Juneteenth commemorates June 19, 1865, the day the last enslaved people in Galveston, Texas, were informed of their freedom, more than two years after the Emancipation Proclamation was issued. That delay is a powerful symbol. It reminds us that declarations of change must be backed by meaningful action, something the clinical research industry still grapples with when it comes to equitable access to clinical trials.

At TFS, we believe that equitable access to clinical research is crucial for enhancing global health outcomes, and this conviction informs how we design, recruit, and conduct studies worldwide. Juneteenth is not only a time for remembrance, but a call to continue dismantling the barriers that prevent underserved communities from participating in, benefiting from, and trusting in the clinical research process.

The Scientific and Ethical Case for Representation

Representation in clinical trials is not just a moral imperative; it’s a scientific one. A lack of diversity among study participants can compromise the quality of clinical data, resulting in therapies that are less effective or less safe for certain populations. Genetic variation, social determinants of health, and differing disease burdens necessitate that therapies be evaluated across diverse groups to ensure their effectiveness.

Yet diversity remains lacking. Despite making up 13% of the U.S. population, Black Americans often comprise less than 10% of trial participants. Hispanic and Indigenous populations face similar underrepresentation. These disparities reflect systemic challenges, including mistrust in healthcare systems, logistical barriers to participation, and study designs that don’t account for cultural or community-specific needs.

Explore actionable steps CROs and sponsors can take to close these gaps.

Acknowledging Historical Mistrust in Medicine

The clinical research industry must continue to acknowledge its complicated history. Unethical practices, from the Tuskegee Syphilis Study to the unauthorized use of Henrietta Lacks’ cells, have left deep and lasting scars. These events have fostered generational mistrust in communities of color, one that still impacts clinical trial enrollment and engagement today.

Juneteenth serves as a reminder that systemic inequities don’t simply fade over time; they must be addressed through transparent, respectful, and inclusive practices.

Discover how Henrietta Lacks’ story continues to impact ethical standards in research today.

Designing Equity into Every Phase of Clinical Research

Achieving equity in clinical trials requires more than awareness. It demands deliberate strategy and consistent execution. At TFS, we support sponsors in embedding inclusion into every phase of the study lifecycle, including:

• Developing diversity action plans at the protocol level, aligned with evolving regulatory guidance and focused on measurable enrollment goals.
• Partnering with community-based organizations and trusted local health centers to build awareness and trust.
• Recruiting investigators and site staff who reflect the communities they serve, improving cultural competency and communication.
• Addressing logistical barriers to participation, such as transportation, childcare, or language accessibility, through thoughtful budgeting and trial logistics.
• Leveraging real-time data monitoring tools to track recruitment diversity and adjust as needed.

These are not just operational choices, but commitments to scientific rigor, ethical responsibility, and the diverse patients we serve.

Why Equity in Clinical Trials Matters Now More Than Ever

Clinical Trial sponsors today face more scrutiny than ever, not only in terms of scientific validity, but also in their role in ensuring access and equity. Regulators, advocacy groups, and patients alike are pushing for greater transparency and representation.

Juneteenth is a powerful reminder that declarations of equity are only the first step. Equitable access to clinical research must be part of the solution, not a footnote in the process. Inclusion doesn’t happen by default. It happens by design.

Join TFS in Building a More Inclusive Research Future

TFS is proud to partner with sponsors who share our commitment to diversity, inclusion, and equity in clinical research. If you’re a biotech or pharmaceutical company seeking to drive better outcomes through broader access or a professional passionate about building a more inclusive research landscape, we want to hear from you.

Connect with our team or explore our careers today!